Yanzhen Guo
机构：Henan University of Science and Technology, First Affiliated Hospital of Henan University of Science and Technology
发表论文 34 篇 · 总被引 444 次 · h-index 10
代表论文
- Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial (2022 · The Lancet. Gastroenterology & hepatology · 被引 88)
- Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study (2023 · The Lancet Respiratory Medicine · 被引 75)
- Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma (2022 · JAMA Oncology · 被引 61)
- Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study (2022 · Journal of Thoracic Oncology · 被引 31)
- Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study (2024 · European Journal of Cancer · 被引 21)
- Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study (2025 · The Lancet Respiratory Medicine · 被引 17)